耐多药结核病全口服短程治疗新进展

New progress in short course-treatment of multidrug resistant tuberculosis by oral administration

耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)是严重危害公共卫生和健康安全的传染病。抗结核治疗不规范以及耐药结核菌的人际传播都能导致新发的耐多药结核病例,由于该病治疗时间长、费用高、毒性大,治疗失败率和疾病复发率高,亟需新的治疗思路来改善耐多药结核病治疗结局。随着更多疗效性及安全性更优的口服药物问世,全口服短程治疗有望成为未来耐药结核病治疗的主要策略,文章将综述这一领域的最新进展。

Multidrug-resistant tuberculosis(MDR-TB)is an infectious disease that seriously endangers public health and health. Non-standard anti-TB treatment and human-to-human transmission of drug-resistant Mycobacterium tuberculosis(MTB)can lead to new cases of MDR-TB. Due to the long treatment time,high cost,high toxicity,and high rate of treatment failure and disease recurrence,new treatment ideas are urgently needed to improve the treatment outcome of MDR-TB.With the advent of more oral drugs with better efficacy and safety,totally oral short-course therapy is expected to become the main strategy for the treatment of drug-resistant TB in the future.This paper reviews the latest progress in this field.